IPIC Message Board - Msg: 2481809

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Dec 18 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (798)	10/18/1997 12:11:00 AM
From: Cacaito	of 1359

NeuroInvestment, Ergotamine, Methysergide have for long being in disorders of serotonine abnormalities and fibrosis of different organs like the best known entity of retroperitoneal fibrosis, in animals and humans. Also, implicated in heart muscle, endocardial membranes, valvular damage and Aorta sclerotic damage. This compounds share many characteristics with Fenfluramine and Dexfenfluramine and similarity in the physiology of the side effects. I was refering to this relationship when I post about "animal and human studies". Then it is now in retrospect not a surprise the recent reports about valvular damage. Causality, not proven yet, but there is a physiologic plausibility and already the actual suspicious data on damage. If it will ever be proven or not is a different question I agree. I check your long review about the companies prospects, quite neat and higly informative. I think if your view is correct there is ample time to wait and see. Only very aggresive, and money to spare investors will jump at this time. I have to admit that my dire prognostics view about the company has changed with the exchange, now I do think there is some chance for the company to survive. Respectfully, cacaito

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next